Drugs that contain Bosutinib Monohydrate

1. Drug name - BOSULIF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE42376 PF PRISM CV Substituted 3-cyanoquinolines
Apr, 2024

(1 year, 6 months from now)

US7767678 PF PRISM CV Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same
Nov, 2026

(4 years from now)

CN101248047A PF PRISM CV Crystalline Forms Of 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Methoxy-7-[3-(4-Methyl-1-Piperazinyl) Propoxy]-3-Quinolinecarbonitrile And Methods Of Preparing The Same
Jan, 2010

(12 years ago)

EP1902029B1 PF PRISM CV Crystalline Forms Of 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Methoxy-7-[3-(4-Methyl-1-Piperazinyl)Propoxy]-3-Quinolinecarb-Onitrile And Methods Of Preparing The Same
Jun, 2026

(3 years from now)

EP1902029B2 PF PRISM CV Crystalline Forms Of 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Methoxy-7-[3-(4-Methyl-1-Piperazinyl)Propoxy]-3-Quinolinecarb-Onitrile And Methods Of Preparing The Same
Jun, 2026

(3 years from now)

EP1902029A1 PF PRISM CV Crystalline Forms Of 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Methoxy-7-[3-(4-Methyl-1-Piperazinyl)Propoxy]-3-Quinolinecarb-Onitrile And Methods Of Preparing The Same
Jun, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7417148 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) Dec, 2025

(3 years from now)

US7919625 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) Dec, 2025

(3 years from now)

US11103497 PF PRISM CV Treatment of imatinib resistant leukemia Feb, 2034

(11 years from now)

Treatment: A method of treating chronic myelogenous leukemia; A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at 949t>c; a method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at f317l

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE TABLET;ORAL Prescription
EQ 400MG BASE TABLET;ORAL Prescription
EQ 500MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.